Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Molecular Partners (MOLN – Research Report), ...
Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the U.S., the release ...
Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® ...
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results